SCHEMBL623986

SCHEMBL623986

Nc1nccc(-c2cccs2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 1.00
KDM4E B2RXH2 7/20 1.00
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
MAPT P10636 3/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
HPGD P15428 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
HSP90AA1 P07900 2/20 0.56
NPC1 O15118 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
CYP1A2 P05177 2/20 0.55
CYP3A4 P08684 2/20 0.55
CYP2C19 P33261 2/20 0.55
HSD17B10 Q99714 2/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CDC7 O00311 1/20 0.54
GAA P10253 2/20 0.54
GLA P06280 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4214452 0.90 ALDH1A1 (0.81) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL4214453 0.82 KDM4E (0.69) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL13977314 0.82 KDM4E (0.69) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL2345970 0.81 ALDH1A1 (0.69) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL30753787 0.79 KDM4E (0.64) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL27733015 0.79 KDM4E (0.65) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL7476570 0.78 KDM4E (0.64) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL14204220 0.78 ALDH1A1 (0.64) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL13610287 0.78 KDM4E (0.66) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL9438552 0.78 ALDH1A1 (0.64) ALDH1A1KDM4EMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118895454-A High-strength alloy steel hot rolled plate and preparation process thereof 河北纵横集团丰南钢铁有限公司 2024-11-05 CN claimed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US claimed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 EP claimed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 WO claimed
CN-118895454-A High-strength alloy steel hot rolled plate and preparation process thereof 河北纵横集团丰南钢铁有限公司 2024-11-05 CN disclosed
CN-110684020-B 2-aminopyrimidine derivatives, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-01-20 CN disclosed
CN-110684020-A 2-aminopyrimidine derivatives, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2020-01-14 CN disclosed
EP-2603214-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2013-06-19 EP disclosed
CN-102834387-A Phenylpyri(mi)dinylpyrazoles and their use as fungicides BAYER CROPSCIENCE AG 2012-12-19 CN disclosed
WO-2012021696-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
CN-102203086-A Thienylamino pyrimidines for use as fungicides BAYER CROPSCIENCE AG 2011-09-28 CN disclosed
US-20050277640-A1 Pyrimidine derivatives for treatment of hyperproliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2005-12-15 US disclosed
US-20050256121-A1 e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma CHIRON CORPORATION (US) 2005-11-17 US disclosed
WO-2005095386-A1 SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS CHIRON CORPORATION (US) 2005-10-13 WO disclosed
WO-2005035507-A2 4-AMINOPYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2005-04-21 WO disclosed
CN-1168721-C 5-cyano-2-aminopyrimidine derivatives О 2004-09-29 CN disclosed
CN-1370152-A 5-cyano-2-aminopyrimidine derivatives CELLETECH CHIROSCIENCE LTD (GB) 2002-09-18 CN disclosed
US-4876252-A ADMINISTERING ANTIASTHMATIC OR ANTIALLERGEN AMERICAN CYANAMID COMPANY (US) 1989-10-24 US disclosed
US-4788195-A TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS AMERICAN CYANAMID COMPANY (US) 1988-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256121-A1 e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma MALT1, AKT1, PIK3CA ALDH1A1 2305/4885KDM4E 283/4885MEN1 1627/4885
US-20050277640-A1 Pyrimidine derivatives for treatment of hyperproliferative disorders TYMP, DPYD, CCNA2 ALDH1A1 1122/4885KDM4E 2029/4885MEN1 2266/4885
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors HSP90AB1, HSP90AB2P, HSP90B1 ALDH1A1 3114/4885KDM4E 4124/4885MEN1 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.